eXoZymes Partners With B2i Digital to Showcase Cell-Free Biomanufacturing Platform
eXoZymes Inc. has been selected as a B2i Digital Featured Company, highlighting its cell-free, AI-guided enzyme platform that offers a scalable alternative to traditional petrochemical processes and synthetic biology methods.
eXoZymes Inc. has been named a B2i Digital Featured Company, bringing attention to its innovative cell-free, AI-guided enzyme platform that represents a significant advancement in sustainable biomanufacturing. The partnership will showcase eXoZymes' technology to B2i Digital's sophisticated investor community, highlighting the platform's potential to address scale-up bottlenecks in industrial biotechnology.
The company's cell-free enzyme technology offers partners access to design and run enzyme pathways for producing target chemicals, providing a scalable alternative to petrochemical processes, natural extraction, and traditional synthetic biology methods. David Shapiro, CEO of B2i Digital, stated that the company offers a timely story for investors focused on sustainable industrial biotechnology, noting that the platform aims to replace selected petrochemical processes with lower-impact biosolutions.
Michael Heltzen, CEO of eXoZymes, emphasized that the partnership with B2i Digital will help communicate the commercial potential of their exozymes platform to the investment community. He believes the next generation of biomanufacturing is cell-free and that this collaboration will enhance visibility among investors who understand the value of their scalable enzyme-based approach. The company initially targets low volume, high value natural products with potential for pharmaceutical applications.
eXoZymes represents a historic first in biomanufacturing by freeing enzyme-driven chemical reactions from cellular limitations. The company's advanced enzymes, called exozymes, are enhanced through AI and bioengineering to thrive in bioreactors without using living cells. This technology transforms biomass into essential natural products, medicines, chemicals, and biofuels, offering partners a commercially viable path to scalable and sustainable production of small molecules at industrial scale.
B2i Digital partners with leading investor conferences, public companies, and capital markets advisors through its Featured Conference, Featured Company, and Featured Expert programs. The firm's proprietary network of over 1.4 million market participants and its experience in supporting investor conferences make it a trusted partner for issuers and investors. More information about B2i Digital can be found at https://b2idigital.com.
eXoZymes has developed a biomanufacturing platform that offers tools to design, engineer, control and optimize natural processes to produce chemical compounds. The company's technology enables partners to upgrade traditional petrochemical production methods with a commercially scalable, sustainable, and eco-friendly alternative using exozymes. Additional information about eXoZymes is available at https://exozymes.com.